How AI Reversed Sarah’s $18,000 Denial and Saved Her Treatment Timeline
Sarah T., a vibrant 58-year-old art gallery manager, was facing a recurrence of ovarian cancer. Her oncologist recommended a specialized chemotherapy regimen combined with a newly approved targeted therapy drug. This drug offered a significant survival advantage for her specific genetic markers.
The financial blow landed hard: the insurer denied